Related Experiment Video
Updated: Jun 21, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Epigenetic deregulation of DNA repair and its potential for therapy
Monika E Hegi1, Davide Sciuscio, Anastasia Murat
1Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland. Monika.Hegi@chuv.ch
Abstract:
Epigenetic silencing of essential components of DNA repair pathways is a common event in many tumor types, and comprise O6-methylguanine-DNA methyltransferase (MGMT), human mut L homolog 1 (hMLH1), Werner syndrome gene (WRN), breast cancer susceptibility gene 1 (BRCA1), and genes of the Fanconi anemia pathway. Most interestingly, some of these alterations become the Achilles heel of the affected tumors upon treatment with certain classes of anticancer agents. That is, patients whose tumors carry such defects can be stratified for respective therapy rendering some classic DNA damaging agents, such as alkylators or DNA crosslinking agents, into "targeted therapies." Here we review some of the affected repair pathways that, when inactivated, sensitize the tumors to specific drugs and are thus exploitable for individualized therapy.
Insights
Epigenetic silencing of DNA repair genes like MGMT and BRCA1 creates vulnerabilities in tumors. These defects can be exploited for targeted cancer therapies using specific DNA damaging agents.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epigenetic silencing of DNA repair genes is frequent in tumors.
- Key genes affected include MGMT, hMLH1, WRN, BRCA1, and Fanconi anemia pathway genes.
Purpose of the Study:
- To review DNA repair pathways that, when inactivated, sensitize tumors to specific drugs.
- To highlight the potential for individualized therapy based on these defects.
Main Methods:
- Literature review of epigenetic silencing in DNA repair pathways.
- Analysis of how pathway inactivation impacts drug sensitivity.
- Discussion of therapeutic implications for personalized medicine.
Main Results:
- Inactivated DNA repair pathways can render tumors susceptible to specific anticancer agents.
- Defects in pathways like MGMT and BRCA1 can be exploited for targeted therapy.
- This stratification allows classic DNA damaging agents to function as targeted therapies.
Conclusions:
- Exploiting epigenetic silencing of DNA repair pathways offers a promising avenue for individualized cancer treatment.
- Understanding these vulnerabilities enables the development of targeted therapies for specific patient populations.
- This approach transforms traditional DNA damaging agents into precision medicines.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Overview of DNA Repair
Chemically...
Overview of DNA Repair
Chemically...
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

